A method, system, apparatus, device, and program product for predicting progression of tension pneumothorax

Abstract

The application provides a method, system, device, equipment and program product for predicting the progression of tension pneumothorax, the method is based on computer and comprises the following steps: obtaining POCUS affected partition count data of a to-be-tested sample; performing classification prediction based on the POCUS affected partition count data to obtain a classification result of the risk level of the to-be-tested sample in terms of the occurrence of cycle collapse of tension pneumothorax; if the POCUS affected partition count data of the to-be-tested sample is greater than or equal to 4, the classification result of the high risk of the to-be-tested sample in terms of the occurrence of cycle collapse of tension pneumothorax is obtained; and if the POCUS affected partition count data of the to-be-tested sample is less than 4, the classification result of the low risk of the to-be-tested sample in terms of the occurrence of cycle collapse of tension pneumothorax is obtained.

Description

Technical Field

[0001] This invention belongs to the field of intelligent medical care, and specifically relates to a method, system, device, equipment and program product for predicting the progression of tension pneumothorax. Background Technology

[0002] Tension pneumothorax (TP) is a life-threatening emergency, especially in trauma care, where rapid identification and immediate treatment are crucial for patient survival.

[0003] However, the diagnosis of pneumothorax is currently mainly qualitative, with clinicians typically making a binary judgment of "pneumothorax present" or "pneumothorax absent" based on signs. There is a lack of validated, quantifiable indicators to provide early warning of impending circulatory collapse and guide clinical decision-making.

[0004] Furthermore, in normal times, with sufficient medical resources, tension pneumothorax on either side can be treated promptly and effectively for an individual. However, in frontline medical care during wartime or disaster relief, due to the large number of casualties and the simultaneous need to treat a significant number of patients potentially suffering from tension pneumothorax, the order of treatment becomes crucial. This underscores the urgent need for validated and quantifiable indicators. Summary of the Invention

[0005] In view of this, in order to overcome the shortcomings of the prior art, the present invention is proposed.

[0006] The first aspect of the present invention provides a method for predicting the progression of tension pneumothorax, the method being computer-based and comprising:

[0007] Obtain the POCUS affected partition count data of the sample to be tested;

[0008] Based on the POCUS affected zonal count data, classification prediction is performed to obtain the classification results of the risk of circulatory collapse in the tension pneumothorax of the test sample.

[0009] If the number of affected POCUS regions in the test sample is ≥4, the test sample is classified as having a high risk of circulatory collapse due to tension pneumothorax; if the number of affected POCUS regions in the test sample is <4, the test sample is classified as having a low risk of circulatory collapse due to tension pneumothorax.

[0010] In this invention, the POCUS affected zone count data refers to the number of zones exhibiting "barcode signs" or disappearance of lung gliding in the M mode of POCUS after being divided according to the six-zone method. The six-zone method refers to dividing each side of the chest into six regions: anterior (upper and lower), lateral (upper and lower), and posterior (upper and lower).

[0011] In this invention, POCUS (point-of-care ultrasound) refers to a portable or handheld color Doppler ultrasound diagnostic device, which is characterized by its small size, ease of operation, and suitability for bedside and field environments.

[0012] In some implementations, the POCUS may include, but is not limited to, the following forms: handheld probe type, tablet or mobile phone connected type, and laptop portable ultrasound device.

[0013] In some implementations, the POCUS is not limited to a specific manufacturer or model, but may be a portable color Doppler ultrasound device manufactured by companies such as Philips, GE, Mindray, and Butterfly Network.

[0014] In this invention, the cycle collapse is defined as cardiac output (CO) ≤ 50% of baseline.

[0015] A second aspect of the present invention provides a system for predicting the progression of tension pneumothorax, the system comprising:

[0016] Acquisition module: Acquires the POCUS affected partition count data of the sample to be tested;

[0017] Prediction module: Based on the POCUS affected partition count data, classification prediction is performed to obtain the classification result of the risk of circulatory collapse in the tension pneumothorax of the test sample;

[0018] If the number of affected POCUS regions in the test sample is ≥4, the test sample is classified as having a high risk of circulatory collapse due to tension pneumothorax; if the number of affected POCUS regions in the test sample is <4, the test sample is classified as having a low risk of circulatory collapse due to tension pneumothorax.

[0019] Output module: Used to output classification results.

[0020] A third aspect of the present invention provides a clinical decision-making method for tension pneumothorax, the method being computer-based and comprising:

[0021] Obtain sample POCUS affected region count data and tension pneumothorax lateral information, wherein tension pneumothorax lateral information includes left and / or right side;

[0022] Clinical decision-making recommendations are given based on the affected zonal count data of POCUS and the lateral information of tension pneumothorax.

[0023] If the sample is a right-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 3 measures" is given; if the sample is a left-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 2 measures" is given; if the sample is a left and right-sided tension pneumothorax and the POCUS affected area count is ≥4 on both sides, a clinical decision recommendation of "taking level 1 measures" is given.

[0024] In this invention, the first-level measures have the highest response strength, followed by the second-level measures, and then the third-level measures.

[0025] In this invention, Level 1 measures have the highest response intensity and require the most decisive and rapid intervention; Level 2 and Level 3 measures decrease in intensity sequentially. Accordingly, when multiple samples simultaneously present with tension pneumothorax, the clinical decision-making system should follow the following priority rules: samples recommended for Level 1 measures should be treated in a higher order than samples recommended for Level 2 or Level 3 measures; samples recommended for Level 2 measures should be treated in a higher order than samples recommended for Level 3 measures.

[0026] A fourth aspect of the present invention provides a clinical decision-making system for tension pneumothorax, the system comprising:

[0027] Acquisition module: Acquires sample POCUS affected region count data and tension pneumothorax lateral information, wherein tension pneumothorax laterality includes left and / or right side;

[0028] Clinical decision-making recommendation module: Provides clinical decision-making recommendations based on the affected zonal count data of the POCUS and the lateral information of the tension pneumothorax;

[0029] If the sample is a right-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 3 measures" is given; if the sample is a left-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 2 measures" is given; if the sample is a left and right-sided tension pneumothorax and the POCUS affected area count is ≥4 on both sides, a clinical decision recommendation of "taking level 1 measures" is given.

[0030] The fifth aspect of the present invention provides an apparatus or device comprising a first computing device, the first computing device including a memory and a processor; the memory being used to store program instructions; the processor being used to invoke the program instructions, which, when executed, implement the steps of the method for predicting the progression of tension pneumothorax as described in the first aspect of the present invention, and / or the steps of the clinical decision-making method for tension pneumothorax as described in the third aspect of the present invention.

[0031] In some implementations, the processor may be one or more.

[0032] In some implementations, the processor includes, but is not limited to, controllers, integrated circuits, microchips, and computers.

[0033] In some implementations, the apparatus or device may include, but is not limited to, POCUS instruments, user interface devices, and user interface devices.

[0034] In some implementations, the user interface device includes a local computing device and a remote computing device.

[0035] A fourth aspect of the present invention provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program, when executed by a processor, implements the steps of the method for predicting the progression of tension pneumothorax as described in the first aspect of the present invention, and / or the steps of the clinical decision-making method for tension pneumothorax as described in the third aspect of the present invention.

[0036] The fifth aspect of the present invention provides a computer program product, which, when executed by a processor, implements the steps of the method for predicting the progression of tension pneumothorax as described in the first aspect of the present invention, and / or the steps of the clinical decision-making method for tension pneumothorax as described in the third aspect of the present invention.

[0037] The advantages and beneficial effects of this invention are as follows:

[0038] (1) This invention proposes and verifies a method for predicting the progression of tension pneumothorax. This method accurately predicts the risk of circulatory collapse based on the counting of affected areas of POCUS, overcoming the limitation of existing technologies that can only make binary judgments of "presence" or "absence".

[0039] (2) The method provided by the present invention can provide reliable ultrasound early warning signals before the cycle collapses, providing technical support for rapid treatment in battlefield, pre-hospital and emergency environments;

[0040] (3) This invention quantifies the potential impact of anatomical asymmetry between the left and right pleural cavities on the pathophysiology of TP and provides a clinical decision-making method for tension pneumothorax, which is of great significance for frontline treatment in war zones or disaster relief sites. Attached Figure Description

[0041] Figure 1 This is a schematic flowchart of a method for predicting the progression of tension pneumothorax provided in an embodiment of the present invention;

[0042] Figure 2This is an experimental method and key POCUS sign diagram. (A) is a schematic diagram of the six-zone ultrasound. The anterior axillary line (AAL) and posterior axillary line (PAL) are used as longitudinal landmarks to divide the chest wall into three regions: anterior, middle, and posterior. Each region is further subdivided into upper and lower zones, forming a total of six standard examination zones: anterior superior zone (1), anterior inferior zone (2), lateral superior zone (3), lateral inferior zone (4), posterior superior zone (5), and posterior inferior zone (6). Cavity A is used for air injection (thin arrow), and cavity B is used to connect the pressure sensor (thick arrow); (B) M-mode "beach sign" of normal lung sliding (indicated by thick arrow); (C) M-mode "barcode sign" of lung sliding disappearance during pneumothorax (indicated by thick arrow);

[0043] Figure 3 This is a dose-response plot of tension pneumothorax progression: (A) Relationship between cumulative insufflation volume and intrapleural pressure (IPP), (B) Relationship between cumulative insufflation volume and number of affected POCUS lesions, and (C) Relationship between cumulative insufflation volume and cardiac output (CO, percentage of baseline). Solid lines represent the right-side model, and dashed lines represent the left-side model. Points represent the mean, and error bars represent the standard deviation (SD). Black dots indicate the threshold points where CO ≤ 50% baseline or POCUS affected lesions = 4.

[0044] Figure 4 This is a graph of the ROC curves for the training and validation sets, with the blue line representing the training set and the red line representing the validation set.

[0045] Figure 5 The images are the imaging evidence for model confirmation. (A) Chest X-ray of the left model: lung collapse on the affected side (thin arrow) and mediastinal shift (thick arrow) are visible. (B) Chest X-ray of the right model: lung collapse on the affected side (thin arrow) and mediastinal shift on the contralateral side (thick arrow) are visible. The red dotted area is the pneumothorax area, showing the typical imaging features used for model confirmation.

[0046] Figure 6 This is a schematic diagram of a system for predicting the progression of tension pneumothorax provided in an embodiment of the present invention;

[0047] Figure 7 This is a schematic flowchart of a clinical decision-making method for tension pneumothorax provided in an embodiment of the present invention;

[0048] Figure 8 This is a graph showing the key differences in tolerance between the left and right sides of the pleural cavity;

[0049] Figure 9 This is a schematic diagram of a clinical decision-making system for tension pneumothorax provided in an embodiment of the present invention;

[0050] Figure 10 This is a schematic diagram of a device provided in an embodiment of the present invention;

[0051] Figure 11 This is another schematic diagram of a device provided in an embodiment of the present invention;

[0052] Figure 12 This is a schematic diagram of a device provided in an embodiment of the present invention;

[0053] Figure 13 This is another schematic diagram of a device provided in an embodiment of the present invention;

[0054] Figure 14 This is a schematic diagram of a device provided in an embodiment of the present invention;

[0055] Figure 15 This is another schematic diagram of a device provided in an embodiment of the present invention;

[0056] Figure 16 This is a schematic diagram of a device provided in an embodiment of the present invention;

[0057] Figure 17 This is a schematic diagram of another device provided in an embodiment of the present invention. Detailed Implementation

[0058] The present invention will be further described below with reference to embodiments. The following description is merely a preferred embodiment of the present invention and is not intended to limit the invention in any other way. Any person skilled in the art may make equivalent modifications to the disclosed technical content to create equivalent embodiments. Any simple modifications or equivalent changes made to the following embodiments based on the technical essence of the present invention without departing from the scope of the invention are all within the protection scope of the present invention.

[0059] In some of the processes described in the specification, claims, and accompanying drawings of this application, multiple operations appearing in a specific order are included. However, it should be clearly understood that these operations may not be performed in the order they appear in this invention, or may be performed in parallel. The operation numbers, such as 101, 102, etc., are merely used to distinguish different operations and do not represent any execution order. Furthermore, these processes may include more or fewer operations, and these operations may be performed sequentially or in parallel.

[0060] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.

[0061] Figure 1This is a schematic flowchart of a method for predicting the progression of tension pneumothorax provided by an embodiment of the present invention. Specifically, the method includes the following steps:

[0062] 101: Obtain the POCUS affected partition count data for the sample under test;

[0063] 102: Based on the POCUS affected zonal count data, classification prediction is performed to obtain the classification results of the risk of circulatory collapse in the test sample with tension pneumothorax;

[0064] If the number of affected POCUS regions in the test sample is ≥4, the test sample is classified as having a high risk of circulatory collapse due to tension pneumothorax; if the number of affected POCUS regions in the test sample is <4, the test sample is classified as having a low risk of circulatory collapse due to tension pneumothorax.

[0065] In some implementations, the cycle collapse is defined as cardiac output ≤ 50% of baseline.

[0066] In some implementations, the relationship between the POCUS-affected partition count data and the cycle crash is obtained by the following method:

[0067] Animal preparation and ethical approvals included in the methodology: Thirty-two healthy adult Bama miniature pigs (mean weight: 45.8 ± 4.4 kg) were enrolled and randomly assigned to either the left or right TP induction group. Animals were anesthetized via intravenous injection of sodium pentobarbital, followed by continuous propofol infusion. All animals received adequate analgesia. After endotracheal intubation, animals were mechanically ventilated (tidal volume 8 mL / kg, PEEP 3–5 mmHg), maintaining end-tidal carbon dioxide (EtCO2) at 35–45 mmHg. A thermodilution catheter was inserted via the femoral artery and connected to a PiCCO system for continuous monitoring of parameters such as CO and MAP.

[0068] The instruments and consumables included in the method are:

[0069] Monitoring and pressure measurement equipment: PiCCO monitor (Pulsion Medical Systems, Feldkirchen, Germany). TruWave PX260 pressure sensor (Edwards Lifesciences, USA).

[0070] Ultrasound equipment: Portable color Doppler ultrasound system CX50 (Philips Ultrasound, Bothell, USA); linear array probe 5–12 MHz, convex array / phased array probe 1–5 MHz.

[0071] Puncture and catheterization consumables: 18G PTC puncture needle (Bard Japan, Tokyo, Japan). Flexible J-shaped guidewire and dilator (to widen the chest wall passage). Dual-lumen central venous catheter (ABLEFV-2766, ABLE Medical, China): Lumen A connects to an injection syringe, and lumen B connects to a pressure sensor. Sterile syringes 20 mL and 60 mL (for injecting saline and air, respectively).

[0072] The method involves the following model construction: The 5th–7th intercostal space along the anterior axillary line is selected as the puncture point. Under precise POCUS localization, local vascular distribution is first assessed using CDFI, avoiding the subcostal vascular and nerve bundles. An 18G puncture needle is used to sequentially penetrate the skin, subcutaneous tissue, and lateral / internal / innermost intercostal muscles to reach the parietal pleura. After the operator feels the needle tip break through the pleura and experiences a loss of resistance, the needle body is fixed and the core is withdrawn, confirming no blood return. 5–10 mL of normal saline is slowly injected. Ultrasound shows the fluid rapidly diffusing along the pleural cavity without forming a localized hypoechoic oval, indicating entry into the pleural cavity. A soft guidewire is then inserted, and ultrasound confirms that its tip is within the pleural cavity (without retraction or accidental entry into the lung parenchyma). After needle withdrawal, the channel is gently dilated along the guidewire using a dilator, and then a double-lumen central venous catheter is inserted. The entire procedure is visualized in real-time under ultrasound. After the catheter is in place, the guidewire is removed, and the flaps are secured with sutures to prevent slippage. One tubing is connected to a pressure sensor to continuously monitor IPP (zeroing at the mid-axillary level), while the other is used to controllably inject air at a rate of 50–100 mL / min in a beat-like manner to simulate progressive air leakage.

[0073] The method involves POCUS assessment and blinding design: Chest POCUS is performed by two experienced operators who remain blinded to real-time hemodynamic parameters (monitoring screen obscured) and cumulative inflation volume. A standardized six-zone pattern (anterior superior / anterior inferior, lateral superior / lateral inferior, posterosuperior / posteroinferior) is used for systematic scanning of each pleural cavity. Figure 2 A). The operator assesses each zone for lung slippage, which manifests as the "sandbar sign" in M-mode (A). Figure 2 B). If lung spondylolisthesis disappears and presents as a "barcode sign" in M ​​pattern, then that region is defined as "affected" (B). Figure 2 C). All ultrasound images were stored for subsequent blinded review by independent assessors.

[0074] The experimental endpoints and safety criteria involved in the method are as follows: The primary endpoint is defined as the occurrence of cyclic collapse, with the operational criterion being a decrease in CO of ≥50% from baseline. For animal safety considerations, several auxiliary termination conditions were also included in the design, including: a significant decrease in MAP or EtCO2 accompanying an increase in IPP, or the appearance of pulseless electrical activity (PEA). It should be noted that these auxiliary criteria are only used for safety monitoring and early termination of gas injection, and are not used as the basis for determining endpoints in diagnostic efficacy analysis.

[0075] In some implementations, the experimental results involved in the method include model induction and hemodynamic evolution: TP was successfully induced in all 32 animals without puncture-related complications. With increasing insufflation volume, the progression of TP showed a clear, quantifiable dose-response relationship: intrapleural pressure (IPP) and the number of affected areas of the POCUS increased accordingly, while cardiac output (CO) decreased accordingly. Figure 3 ).

[0076] When the total pressure (TP) threshold (CO ≤ 50%) was reached, the animals' core vital signs changed dramatically: mean arterial pressure (MAP) decreased from 80.8 ± 4.3 mmHg to 67.2 ± 5.6 mmHg, cardiac output (CO) was halved from 5.45 ± 0.38 L / min to 2.66 ± 0.32 L / min, while heart rate (HR) compensatorily increased from 95.3 ± 5.8 bpm to 110.3 ± 6.7 bpm (all changes P < 0.001, see Table 1).

[0077] Table 1. Hemodynamic changes from baseline to the threshold of ≤50% cardiac output and lateral differences at the inflection point

[0078]

[0079] The inflection point was defined as a ≥50% decrease in cardiac output (CO) from baseline, serving as the diagnostic threshold for tension pneumothorax. Data are expressed as mean ± SD. Hedges' g was used to calculate the left-right effect size.

[0080] In some implementations, the method involves diagnostic efficacy and threshold validation of POCUS partition counting: a decrease in cardiac output to below 50% (≤50%) of baseline is used as the endpoint of circulatory collapse. Animals are divided into a training set of 24 animals and a validation set of 8 animals, and the optimal threshold for the number of affected partitions is determined in the training set. Results ( Figure 4The results showed that when the number of affected partitions was ≥4 / 6, the area under the ROC curve (AUC) was 0.961 (95% CI 0.948–0.972), the sensitivity was 0.861, and the specificity was 0.908. Applying this threshold to the validation set yielded approximately consistent results, demonstrating its robustness.

[0081] In some implementation schemes, the two POCUS operators showed a high degree of consistency in interpreting the extent of zonal involvement (Cohen's κ = 0.75; intraclass correlation coefficient ICC = 0.82), ensuring the reliability of the measurement. Chest X-rays obtained after meeting the intervention criteria confirmed lung collapse on the affected side and mediastinal shift to the contralateral side, completely consistent with the classic imaging findings of TP. Figure 5 ).

[0082] Figure 6 This is a schematic diagram of a system for predicting the progression of tension pneumothorax according to an embodiment of the present invention. The system includes:

[0083] 201: Acquisition Module: Acquires the POCUS affected partition count data of the sample to be tested;

[0084] 202: Prediction module: Based on the POCUS affected partition count data, classification prediction is performed to obtain the classification result of the risk of circulatory collapse in the tension pneumothorax of the test sample;

[0085] If the number of affected POCUS regions in the test sample is ≥4, the test sample is classified as having a high risk of circulatory collapse due to tension pneumothorax; if the number of affected POCUS regions in the test sample is <4, the test sample is classified as having a low risk of circulatory collapse due to tension pneumothorax.

[0086] 203: Output module: Used to output classification results.

[0087] Figure 7 This is a schematic flowchart of a clinical decision-making method for tension pneumothorax provided by an embodiment of the present invention. The method includes:

[0088] 301: Obtain the sample POCUS affected region count data and the lateral information of the tension pneumothorax, wherein the lateral information of the tension pneumothorax includes the left and / or right sides;

[0089] 302: Provide clinical decision recommendations based on the affected zonal count data of the POCUS and the lateral information of the tension pneumothorax;

[0090] If the sample is a right-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 3 measures" is given; if the sample is a left-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 2 measures" is given; if the sample is a left and right-sided tension pneumothorax and the POCUS affected area count is ≥4 on both sides, a clinical decision recommendation of "taking level 1 measures" is given.

[0091] In some implementations, if the sample is left and right tension pneumothorax and only the left POCUS has an affected sectional count data ≥4, then a clinical decision recommendation of "taking secondary measures" is given.

[0092] In some implementations, if the sample is a left and right tension pneumothorax and only the left POCUS has an affected sectional count data ≥4, then a clinical decision recommendation of "taking level 3 measures" is given.

[0093] In this invention, the first-level measures have the highest response strength, followed by the second-level measures, and then the third-level measures.

[0094] In this invention, Level 1 measures have the highest response intensity and require the most decisive and rapid intervention; Level 2 and Level 3 measures decrease in intensity sequentially. Accordingly, when multiple samples simultaneously present with tension pneumothorax, the clinical decision-making system should follow the following priority rules: samples recommended for Level 1 measures should be treated in a higher order than samples recommended for Level 2 or Level 3 measures; samples recommended for Level 2 measures should be treated in a higher order than samples recommended for Level 3 measures.

[0095] In some implementation schemes, Figure 3 This visually demonstrates that the progress of TP on the right side is more "rapid": in the right-side model, a smaller injection volume can cause a sharp increase in IPP ( Figure 3 A) Rapid accumulation of POCUS affected partitions ( Figure 3 B) and the rapid decline in CO ( Figure 3 C), whose response curve is steeper overall. In contrast, the model on the left shows stronger pressure and volume "tolerance," with its various indicators changing relatively smoothly over a wider range of gas injection volumes, only deteriorating sharply near the endpoint. During the experiment, the animals' safety indicators were closely monitored. The results showed that TP was successfully induced in all 32 animals.

[0096] In some implementations, significant differences were observed between the left and right pleural cavities in terms of pressure and volume tolerance. To achieve the endpoint of CO ≤ 50%, the left-sided TP model required a significantly higher mean IPP than the right-sided model (8.40 ± 0.40 mmHg vs. 5.62 ± 0.42 mmHg; P < 0.001). Similarly, the cumulative gas injection volume required to induce circulatory collapse was more than twice that of the left side (14.80 ± 1.11 mL / kg) compared to the right side (7.45 ± 0.81 mL / kg) (P < 0.001). The effect sizes calculated for these differences were: Hedges' g for IPP = 6.26, Hedges' g for gas injection volume = 6.98 (…). Figure 8 ).

[0097] From the perspective of "risk evolution," the danger of right-sided TP lies in its "rapid progression." At the endpoint of circulatory collapse, the right side requires only half the amount of air insufflation as the left, and this can occur at a lower IPP level. This suggests that even a slight increase in right-sided intrathoracic pressure can more directly and effectively compress venous return pathways, leading to a rapid deterioration of hemodynamic status within a short period. Therefore, a higher level of vigilance must be maintained during initial clinical assessments for right-sided pneumothorax, as its condition may progress rapidly beneath a seemingly stable exterior. From the perspective of "interpretation of signs," the danger of left-sided TP lies in its "extreme state." When left-sided TP exhibits the same "≥4 / 6 zone" warning signal as the right, this does not mean that both are at the same pathophysiological stage. On the contrary, this indicates that the left pleural cavity has accumulated far more pressure and gas volume than the right, pushing the entire cardiopulmonary system to its compensatory limit. At this point, "stability" is extremely fragile; any minor disturbance can lead to catastrophic collapse. Therefore, once the left-sided POCUS reaches the warning threshold, the most decisive and rapid decompression measures must be taken, because the underlying pathophysiological state is far more dangerous than that on the right side. Based on the above results, the criteria for giving clinical decision-making recommendations were determined.

[0098] In some implementations, the method for predicting the progression of tension pneumothorax and the method for clinical decision-making regarding tension pneumothorax can be combined, wherein the method can both predict the progression of tension pneumothorax and provide clinical decision-making regarding tension pneumothorax.

[0099] Figure 9 This is a schematic diagram of a clinical decision-making system for tension pneumothorax provided in an embodiment of the present invention. The system includes:

[0100] 401: Acquisition Module: Acquires sample POCUS affected region count data and lateral information of the tension pneumothorax, wherein the lateral information of the tension pneumothorax includes the left and / or right sides;

[0101] 402: Clinical Decision Recommendation Module: Provides clinical decision recommendations based on the affected zonal count data of the POCUS and the lateral information of the tension pneumothorax;

[0102] If the sample is a right-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 3 measures" is given; if the sample is a left-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of "taking level 2 measures" is given; if the sample is a left and right-sided tension pneumothorax and the POCUS affected area count is ≥4 on both sides, a clinical decision recommendation of "taking level 1 measures" is given.

[0103] In this invention, the first-level measures have the highest response strength, followed by the second-level measures, and then the third-level measures.

[0104] In this invention, Level 1 measures have the highest response intensity and require the most decisive and rapid intervention; Level 2 and Level 3 measures decrease in intensity sequentially. Accordingly, when multiple samples simultaneously present with tension pneumothorax, the clinical decision-making system should follow the following priority rules: samples recommended for Level 1 measures should be treated in a higher order than samples recommended for Level 2 or Level 3 measures; samples recommended for Level 2 measures should be treated in a higher order than samples recommended for Level 3 measures.

[0105] In some implementations, the system for predicting the progression of tension pneumothorax and the clinical decision-making system for tension pneumothorax can be combined, the system being able to both predict the progression of tension pneumothorax and provide clinical decisions for tension pneumothorax.

[0106] Figure 10 This is a schematic diagram of a device provided in an embodiment of the present invention. The device includes a first computing device, which includes a memory and a processor. The memory is used to store program instructions. The processor is used to call the program instructions, and when the program instructions are executed, they implement the steps of the method for predicting the progression of tension pneumothorax as described in the first aspect of the present invention.

[0107] In some implementations, the processor may be one or more.

[0108] In some implementations, the processor includes one or more of a controller, an integrated circuit, a microchip, and a computer.

[0109] In some implementations, the apparatus or device further includes one or more of a POCUS instrument, a user interface device, and a user interface device.

[0110] In some implementations, the POCUS instrument, user interface device, and user interface device are each communicatively coupled to the first computing device.

[0111] In this invention, the communication coupling refers to the ability of coupled components to exchange data signals with each other, such as electrical signals via a conductive medium, electromagnetic signals via air, and optical signals via an optical waveguide.

[0112] In some implementations, the user interface device supports user input of the affected partition count data of the POCUS of the sample under test.

[0113] In some implementations, the user interface device supports receiving the results of POCUS instrument testing.

[0114] In some implementations, the user interface device displays the results of the received POCUS instrument test to the user.

[0115] In some implementations, the user interface device displays the prediction results to the user.

[0116] In some implementations, the user interface device includes a local computing device and a remote computing device.

[0117] In some implementation schemes, such as Figure 11 As shown, the user interface device is communicatively coupled with the first computing device. The user inputs the POCUS affected partition count data of the sample to be tested through the user interface device, which is then transmitted to the first computing device. After processing by the first computing device, the prediction result is displayed by the user interface device.

[0118] In some implementation schemes, such as Figure 12 As shown, the POCUS instrument is communicatively coupled to the user interface device, and the user interface device is communicatively coupled to the first computing device. The POCUS instrument detects the number of POCUS-affected partitions in the sample to be tested. The detection result is received by the user interface device and then transmitted to the first computing device. After being processed by the first computing device, the prediction result is displayed by the user interface device.

[0119] Figure 13 This is a schematic diagram of a device provided in an embodiment of the present invention. The device includes a first computing device, which includes a memory and a processor. The memory is used to store program instructions. The processor is used to call the program instructions, and when the program instructions are executed, the steps of the clinical decision-making method for tension pneumothorax described in the third aspect of the present invention are implemented.

[0120] In some implementations, the processor may be one or more.

[0121] In some implementations, the processor includes one or more of a controller, an integrated circuit, a microchip, and a computer.

[0122] In some embodiments, the device further includes one or more of the following: tension pneumothorax lateral determination device, POCUS instrument, user interface device, and user interface device.

[0123] In some implementations, the tension pneumothorax lateral determination device, POCUS instrument, user interface device, and user interface device are each communicatively coupled to a first computing device.

[0124] In this invention, the communication coupling refers to the ability of coupled components to exchange data signals with each other, such as electrical signals via a conductive medium, electromagnetic signals via air, and optical signals via an optical waveguide.

[0125] In some implementations, the user interface device supports user input of tension pneumothorax lateralization.

[0126] In some implementations, the user interface device supports user input of sample POCUS affected partition count data.

[0127] In some implementations, the user interface device supports receiving the results from the tension pneumothorax lateral determination device.

[0128] In some embodiments, the tension pneumothorax lateral determination device is used to determine the side on which tension pneumothorax occurs, including the left and / or right side.

[0129] In some implementations, the user interface device displays to the user the results received from the tension pneumothorax lateral determination device.

[0130] In some implementations, the user interface device supports receiving the results of POCUS instrument testing.

[0131] In some implementations, the user interface device displays the results of the received POCUS instrument test to the user.

[0132] In some implementations, the user interface device displays the results of clinical decision recommendations to the user.

[0133] In some implementations, the user interface device includes a local computing device and a remote computing device.

[0134] In some implementation schemes, such as Figure 14 As shown, the user interface device is communicatively coupled to the first computing device. The user inputs the sample tension pneumothorax lateral and POCUS affected area count data through the user interface device, which is then transmitted to the first computing device. After processing by the first computing device, the clinical decision suggestion results are displayed by the user interface device.

[0135] In some implementation schemes, such as Figure 15As shown, the POCUS instrument is communicatively coupled to the user interface device, which is also communicatively coupled to the first computing device. The user inputs the tension pneumothorax laterality of the sample through the user interface device, and the POCUS instrument detects the number of POCUS-affected lesions in the sample. The detection results are received by the user interface device, and the tension pneumothorax laterality and POCUS-affected lesion count data are transmitted to the first computing device. After processing by the first computing device, the clinical decision suggestion results are displayed by the user interface device.

[0136] In some implementation schemes, such as Figure 16 As shown, the tension pneumothorax lateralization determination device is communicatively coupled to the user interface device, and the user interface device is communicatively coupled to the first computing device. The user inputs the POCUS affected region count data through the user interface device, and the tension pneumothorax lateralization determination device determines the laterality of the tension pneumothorax. The determination result is received by the user interface device. The sample tension pneumothorax lateralization and POCUS affected region count data are transmitted to the first computing device. After processing by the first computing device, the clinical decision suggestion result is displayed by the user interface device.

[0137] In some implementation schemes, such as Figure 17 As shown, the tension pneumothorax lateralization determination device and the POCUS instrument are communicatively coupled to the user interface device, and the user interface device is communicatively coupled to the first computing device. The tension pneumothorax lateralization determination device determines the laterality of the tension pneumothorax, and the POCUS instrument counts the POCUS-affected lesions in the sample. The determination result and the detection result are received by the user interface device and then transmitted to the first computing device. After processing by the first computing device, the clinical decision suggestion result is displayed by the user interface device.

[0138] In some embodiments, the device can both predict the progression of tension pneumothorax and provide clinical decisions for tension pneumothorax. The device includes a first computing device, which includes a memory and a processor. The memory is used to store program instructions. The processor is used to invoke the program instructions, which, when executed, implement the steps of the method for predicting the progression of tension pneumothorax according to the first aspect of the present invention and the steps of the clinical decision-making method for tension pneumothorax according to the third aspect of the present invention.

[0139] Those skilled in the art will readily understand that, in the several embodiments provided by this invention, the disclosed systems, devices, and methods can be implemented in other ways. For example, the device embodiments described above are merely illustrative; for instance, the division of units is only a logical functional division, and in actual implementation, there may be other division methods. For example, multiple units or components may be combined or integrated into another system, or some features may be ignored or not executed. Furthermore, the couplings or direct couplings or communication connections shown or discussed may be indirect couplings or communication connections through some interfaces, devices, or units, and may be electrical, mechanical, or other forms.

[0140] Furthermore, the functional units in the various embodiments of the present invention can be integrated into one processing unit, or each unit can exist physically separately, or two or more units can be integrated into one unit. The integrated units described above can be implemented in hardware or as software functional units. Those skilled in the art will understand that all or part of the steps in the various methods of the above embodiments can be implemented by a program instructing related hardware. This program can be stored in a computer-readable storage medium, which may include: read-only memory (ROM), random access memory (RAM), a magnetic disk, or an optical disk, etc.

[0141] The computer device provided by the present invention has been described in detail above. For those skilled in the art, there will be changes in the specific implementation and application scope based on the ideas of the embodiments of the present invention. Therefore, the content of this specification should not be construed as a limitation of the present invention.

[0142] The above description of the embodiments is only for understanding the method and core ideas of the present invention. It should be noted that those skilled in the art can make various improvements and modifications to the present invention without departing from the principles of the invention, and these improvements and modifications will also fall within the protection scope of the claims of the present invention.

Claims

1. A clinical decision-making method for tension pneumothorax, characterized in that, The method is computer-based and includes: Obtain the POCUS affected zone count data and the lateral information of the tension pneumothorax in the sample to be tested. The lateral information of the tension pneumothorax includes the left and / or right sides. The POCUS affected zone count data is the number of zones with barcode signs or disappearance of lung slippage in the M mode of POCUS after division according to the six-zone method. The six-zone method refers to dividing each side of the chest into six regions: anterior upper, anterior lower, lateral upper, lateral lower, posterior upper, and posterior lower. Based on the POCUS affected zonal count data, classification prediction is performed to obtain the classification results of the risk of circulatory collapse in the tension pneumothorax of the test sample. If the number of affected regions of POCUS in the test sample is ≥4, the classification result of high risk of circulatory collapse in the test sample with tension pneumothorax is obtained, wherein circulatory collapse is defined as cardiac output ≤ 50 of baseline. If the number of affected POCUS zonal counts of the test sample is less than 4, then the classification result of low risk of circulatory collapse in tension pneumothorax of the test sample is obtained. Clinical decision-making recommendations are given based on the affected zonal count data of POCUS and the lateral information of tension pneumothorax. If the sample to be tested is a right-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of Level III intervention is given; if the sample to be tested is a left-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of Level II intervention is given; if the sample to be tested is a left-sided and right-sided tension pneumothorax and the POCUS affected area count on both sides is ≥4, a clinical decision recommendation of Level I intervention is given. The first-level measures have the strongest response, followed by the second-level measures, and then the third-level measures.

2. A clinical decision-making system for tension pneumothorax, characterized in that, The system includes: Acquisition Module: Acquires the POCUS affected zone count data and the lateral information of the tension pneumothorax of the sample to be tested. The lateral information of the tension pneumothorax includes the left and / or right sides. The POCUS affected zone count data is the number of zones with barcode signs or disappearance of lung slippage in the M mode of POCUS after division according to the six-zone method. The six-zone method refers to dividing each side of the chest into six regions: anterior upper, anterior lower, lateral upper, lateral lower, posterior upper, and posterior lower. Clinical decision suggestion module: Based on the count data of affected zonal regions of the POCUS, classification and prediction are performed to obtain the classification results of the risk of circulatory collapse in tension pneumothorax of the test sample; If the number of affected regions of POCUS in the test sample is ≥4, the classification result of high risk of circulatory collapse in the test sample with tension pneumothorax is obtained, wherein circulatory collapse is defined as cardiac output ≤ 50 of baseline. If the number of affected POCUS zonal counts of the test sample is less than 4, then the classification result of low risk of circulatory collapse in tension pneumothorax of the test sample is obtained. Clinical decision-making recommendations are given based on the affected zonal count data of POCUS and the lateral information of tension pneumothorax. If the sample to be tested is a right-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of Level III intervention is given; if the sample to be tested is a left-sided tension pneumothorax and the POCUS affected area count is ≥4, a clinical decision recommendation of Level II intervention is given; if the sample to be tested is a left-sided and right-sided tension pneumothorax and the POCUS affected area count on both sides is ≥4, a clinical decision recommendation of Level I intervention is given. The first-level measures have the strongest response, followed by the second-level measures, and then the third-level measures.

3. A computer device, characterized in that, The computer device includes a first computing device, which includes a memory and a processor; the memory is used to store program instructions; the processor is used to invoke the program instructions, and when the program instructions are executed, to implement the steps of the clinical decision-making method for tension pneumothorax as described in claim 1.

4. The computer device according to claim 3, characterized in that, The processor may be one or more.

5. The computer device according to claim 4, characterized in that, The processor includes one or more of the following: controller, integrated circuit, microchip, and computer.

6. The computer device according to any one of claims 3-5, characterized in that, The device also includes one or more of the following: POCUS instruments, user interface devices, and user interface devices.

7. The computer device according to claim 6, characterized in that, The device also includes a tension pneumothorax lateral determination device.

8. The computer device according to claim 6, characterized in that, The user interface devices include local computing devices and remote computing devices.

9. A computer-readable storage medium having a computer program stored thereon, characterized in that, When the computer program is executed by the processor, it implements the steps of the clinical decision-making method for tension pneumothorax as described in claim 1.

10. A computer program product, characterized in that, When the computer program is executed by the processor, it implements the steps of the clinical decision-making method for tension pneumothorax as described in claim 1.

Images